施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMY 施贵宝

盘前交易 05-06 08:06:16 EDT

56.95

-0.43

-0.75%

盘前57.38

+0.43+0.76%

08:05 EDT

最高57.48	最低56.73	成交量1,132万
今开57.00	昨收57.38	日振幅1.30%
总市值1,159亿	流通市值1,157亿	总股本20.36亿
成交额6.45亿	换手率0.56%	流通股本20.32亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMY","market":"US","secType":"STK","nameCN":"施贵宝","latestPrice":56.95,"timestamp":1778011200000,"preClose":57.38,"halted":0,"volume":11316685,"hourTrading":{"tag":"盘前","latestPrice":57.38,"preClose":56.95,"latestTime":"08:05 EDT","volume":844,"amount":48324.180472,"timestamp":1778069112804,"change":0.43,"changeRate":0.00755,"amplitude":0.012239},"delay":0,"changeRate":-0.007493900313698148,"floatShares":2031646263,"shares":2035753027,"eps":3.569767,"marketStatus":"盘前交易","change":-0.43,"latestTime":"05-06 08:06:16 EDT","open":57,"high":57.48,"low":56.732,"amount":645496639.471875,"amplitude":0.013036,"askPrice":57.54,"askSize":702,"bidPrice":56.95,"bidSize":9,"shortable":3,"etf":0,"ttmEps":3.569767,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778074200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":-18475200000,"exchange":"NYSE","adjPreClose":56.95,"dividendRate":0.0439,"preHourTrading":{"tag":"盘前","latestPrice":57.38,"preClose":56.95,"latestTime":"08:05 EDT","volume":844,"amount":48324.180472,"timestamp":1778069112804,"change":0.43,"changeRate":0.00755,"amplitude":0.012239},"postHourTrading":{"tag":"盘后","latestPrice":56.8741,"preClose":56.95,"latestTime":"19:53 EDT","volume":906398,"amount":51619576.1376,"timestamp":1778025193438,"change":-0.0759,"changeRate":-0.001333,"amplitude":0.002562},"volumeRatio":0.8268833492163574,"impliedVol":0.284,"impliedVolPercentile":0.184},"requestUrl":"/m/hq/s/BMY","defaultTab":"news","newsList":[{"id":"1144973551","title":"异动解读 | 施贵宝盘中大涨5.09%，季度利润超预期且重申积极业绩指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1144973551","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144973551?lang=zh_cn&edition=full","pubTime":"2026-05-01 03:54","pubTimestamp":1777578891,"startTime":"0","endTime":"0","summary":"施贵宝（BMY）今日盘中大涨5.09%，引起了市场的广泛关注。消息面上，公司公布的季度利润超出华尔街预期，主要得益于抗凝血药艾乐妥（Eliquis）及新型抗癌药物的销售表现强劲。同时，公司重申了2026年财务业绩指引，并预计实际业绩将趋向预期区间的上限，这增强了投资者对公司盈利能力的信心。此外，公司高管在电话会议中强调，业务发展是资本配置的首要任务，并指出公司拥有充足的财务灵活性以寻求战略并购机会，进一步支撑了市场对其长期增长前景的乐观情绪。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182260895","title":"施贵宝高管重申业务发展仍为资本配置首要任务 - 电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1182260895","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182260895?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:30","pubTimestamp":1777552212,"startTime":"0","endTime":"0","summary":"在最新电话会议中，施贵宝公司高管强调，业务发展将继续作为公司资本配置的最高优先级。这一表态凸显了该制药巨头通过战略性投资驱动长期增长的坚定承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1261432733.SGD","BK4585","LU1074936037.SGD","LU1868836591.USD","LU2360032135.SGD","LU1323610961.USD","LU1291159041.SGD","IE00BJT1NW94.SGD","LU0306807586.USD","IE0009355771.USD","LU0306806265.USD","LU0321505868.SGD","LU0985481810.HKD","LU2133065610.SGD","LU1868837136.USD","LU1670711123.USD","LU0882574055.USD","IE00B2B36J28.USD","LU1983299246.USD","BK4588","LU1430594728.SGD","LU0225771236.USD","LU1585245621.USD","BMY","LU1989771016.USD","LU1093756168.USD","LU1883839398.USD","LU0321505439.SGD","LU1571399168.USD","BK4559","LU1670710661.SGD","LU0432979614.USD","LU0114720955.EUR","LU1032466523.USD","LU0267386448.USD","LU2125154935.USD","IE0002141913.USD","IE00BSNM7G36.USD","LU1868836914.USD","IE00BFXG1179.USD","BK4534","IE00BFTCPJ56.SGD","LU0456855351.SGD","LU1868837300.USD","LU2125154778.USD","LU1670711040.USD","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU2242646821.SGD","LU0096364046.USD","LU0237698245.USD","LU0061475181.USD","BK4532","LU2242652126.USD","LU0225284248.USD","LU1718418525.SGD","LU0868494617.USD","BK4581","LU1670710588.SGD","LU1868836757.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111101960","title":"施贵宝重申2026财年指引：总营收与调整后每股收益预计将达区间高端","url":"https://stock-news.laohu8.com/highlight/detail?id=1111101960","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111101960?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:59","pubTimestamp":1777546764,"startTime":"0","endTime":"0","summary":"制药巨头施贵宝(Bristol-Myers Squibb)近日重申了其2026年度的财务业绩指引。公司表示，目前各项运营指标显示，全年总营收和调整后每股收益均有望达到此前预期范围的上限水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837300.USD","LU1323610961.USD","LU1670710661.SGD","LU1983299246.USD","IE00BSNM7G36.USD","LU1868837136.USD","LU2125154935.USD","LU1670710588.SGD","LU0061475181.USD","LU1670711123.USD","BK4007","LU1989771016.USD","LU0306806265.USD","LU2242652126.USD","IE00BFXG1179.USD","LU0237698245.USD","LU1868836914.USD","LU1261432733.SGD","LU0882574055.USD","IE0002141913.USD","LU1032466523.USD","LU0432979614.USD","LU0096364046.USD","IE00BFTCPJ56.SGD","BK4585","LU2360032135.SGD","LU1868836591.USD","BMY","BK4559","LU1670711040.USD","BK4534","LU0306807586.USD","LU1074936037.SGD","LU1718418525.SGD","LU1585245621.USD","IE00B2B36J28.USD","LU0321505868.SGD","LU0985481810.HKD","LU2125154778.USD","LU1093756325.SGD","LU2242646821.SGD","LU1093756168.USD","LU1868836757.USD","LU1883839398.USD","LU0321505439.SGD","LU0225771236.USD","LU1571399168.USD","LU1291159041.SGD","LU1430594728.SGD","BK4532","BK4581","IE0009355771.USD","IE00BJT1NW94.SGD","LU0456855351.SGD","LU0114720955.EUR","LU0225284248.USD","LU0267386448.USD","LU0868494617.USD","IE00BJJMRZ35.SGD","LU2133065610.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631537129","title":"上海医药清仓中美施贵宝 高瓴系公司接盘；百洋医药一季度净利润增加近46% | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2631537129","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631537129?lang=zh_cn&edition=full","pubTime":"2026-04-29 07:04","pubTimestamp":1777417480,"startTime":"0","endTime":"0","summary":"丨2026年4月29日星期三丨NO.1泰格医药一季度净利润同比减少70.36%4月28日，泰格医药发布2026年一季报，公司实现营业收入18.01亿元，同比增加15.17%；实现归属于上市公司股东的净利润4904.31万元，同比减少70.36%；实现归属于上市公司股东的扣除非经常性损益的净利润1.20亿元，同比增加17.65%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604293723254882.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604293723254882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["301015","601607","BMY","02607","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101600364","title":"施贵宝与辉瑞将通过马克·库班成本加成药房提供Eliquis®（阿哌沙班）","url":"https://stock-news.laohu8.com/highlight/detail?id=1101600364","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101600364?lang=zh_cn&edition=full","pubTime":"2026-04-24 19:01","pubTimestamp":1777028460,"startTime":"0","endTime":"0","summary":"施贵宝（Bristol Myers Squibb）与辉瑞（Pfizer）宣布，双方将合作通过马克·库班成本加成药房（Mark Cuban Cost Plus Drug Company）渠道向患者提供抗凝血药物Eliquis®（阿哌沙班）。这一举措旨在扩大该药物的可及性，为更多需要抗凝治疗的患者提供用药选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670711040.USD","LU1032466523.USD","LU0985481810.HKD","LU1989771016.USD","BK4599","LU1323610961.USD","LU0306806265.USD","LU0321505868.SGD","BK4585","BK4533","LU0237698245.USD","LU0061475181.USD","SG9999002224.SGD","LU0306807586.USD","LU1093756168.USD","IE00BLSP4452.SGD","BK4568","LU1868837300.USD","LU2133065610.SGD","LU0432979614.USD","LU1585245621.USD","LU1983299246.USD","IE00BJJMRZ35.SGD","LU1291159041.SGD","LU1868837136.USD","LU1066053197.SGD","BK4592","SG9999013999.USD","LU1868836914.USD","LU2125154935.USD","IE0009355771.USD","BK4559","LU0868494617.USD","LU1894683348.USD","IE00BSNM7G36.USD","LU1670711123.USD","LU0225771236.USD","IE0002270589.USD","BK4550","LU0321505439.SGD","IE00BJT1NW94.SGD","BK4588","BK4532","LU1066051498.USD","SG9999001176.USD","LU2125154778.USD","SGXZ57979304.SGD","LU0882574055.USD","LU2242652126.USD","LU1868836757.USD","IE00BBT3K403.USD","LU0096364046.USD","PFE","IE00BLSP4239.USD","BK4581","IE0002141913.USD","LU2242646821.SGD","LU0456855351.SGD","LU1261432733.SGD","LU0058720904.USD","BMY","LU0170899867.USD","SG9999011175.SGD","SG9999001176.SGD","LU1571399168.USD","LU2360032135.SGD","BK4007","LU1883839398.USD","LU1093756325.SGD","LU1894683264.USD","LU0267386448.USD","IE00B19Z3B42.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU1430594728.SGD","LU0114720955.EUR","SG9999002232.USD","LU1868836591.USD","LU1670710661.SGD","LU0122379950.USD","LU0234572021.USD","SG9999003800.SGD","LU1057294990.SGD","LU1023059063.AUD","LU1718418525.SGD","IE000M9KFDE8.USD","IE00B19Z3581.USD","IE00BFXG1179.USD","LU1670710588.SGD","BK4534","LU0289739699.SGD","LU0225284248.USD","LU1074936037.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153341014","title":"财报前瞻｜施贵宝本季营收预计小幅回升，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1153341014","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153341014?lang=zh_cn&edition=full","pubTime":"2026-04-23 23:56","pubTimestamp":1776959790,"startTime":"0","endTime":"0","summary":"施贵宝将于2026年04月30日发布财报，市场预期本季收入温和增长而盈利承压。市场一致预期显示，本季度施贵宝营收预计为108.52亿美元，同比增加1.46%；预计调整后每股收益为1.41美元，同比下降5.57%；预计息税前利润为36.84亿美元，同比小幅增长0.54%。基于近半年内主流机构对施贵宝的舆论与观点收集，偏谨慎的声音占比更高。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜施贵宝本季营收预计小幅回升，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105218816","title":"Atrium Therapeutics获施贵宝心血管合作1500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1105218816","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105218816?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:04","pubTimestamp":1776945856,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics宣布，根据其与施贵宝达成的全球心血管领域合作协议，公司已成功获得一笔1500万美元的里程碑付款。此次付款标志着双方合作取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","IE00BSNM7G36.USD","LU1868836591.USD","LU1291159041.SGD","BK4532","BK4585","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU1868837136.USD","RNA","LU1323610961.USD","LU1571399168.USD","BK4139","LU0061475181.USD","BK4581","IE0009355771.USD","IE00BFTCPJ56.SGD","LU2360032135.SGD","BK4588","BMY","BK4505","LU0114720955.EUR","IE00B2B36J28.USD","LU0096364046.USD","LU1093756168.USD","LU0432979614.USD","LU1868836914.USD","LU1032466523.USD","LU0225771236.USD","LU1883839398.USD","LU2125154778.USD","IE0009354923.USD","BK4007","LU1868836757.USD","LU0882574055.USD","LU0321505439.SGD","LU0237698245.USD","LU1074936037.SGD","LU0267386448.USD","IE00BJT1NW94.SGD","BK4559","LU0306806265.USD","LU0306807586.USD","LU0456855351.SGD","LU1670710661.SGD","LU1868837300.USD","LU1585245621.USD","BK4534","LU0321505868.SGD","LU1718418525.SGD","LU2133065610.SGD","LU0225284248.USD","LU0868494617.USD","LU0985481810.HKD","LU1989771016.USD","LU2242646821.SGD","IE00BFXG1179.USD","LU2242652126.USD","LU1670710588.SGD","LU1670711040.USD","LU1670711123.USD","LU1261432733.SGD","LU1983299246.USD","LU1430594728.SGD","LU2125154935.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181426981","title":"施贵宝将全面资助Atrium Therapeutics合作项目未来所有临床、注册及商业化活动","url":"https://stock-news.laohu8.com/highlight/detail?id=1181426981","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181426981?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:03","pubTimestamp":1776945801,"startTime":"0","endTime":"0","summary":"根据最新合作协议条款，施贵宝（Bristol Myers Squibb）将承担与Atrium Therapeutics合作项目后续所有临床开发、注册申报及商业化活动的全部资金。这一安排标志着双方战略合作进入新阶段，由施贵宝主导推进项目全球化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","IE00BJT1NW94.SGD","BK4581","LU1093756325.SGD","LU0114720955.EUR","LU2125154778.USD","LU0267386448.USD","LU1868836914.USD","LU2242652126.USD","LU0225771236.USD","LU1291159041.SGD","LU2125154935.USD","LU1670711040.USD","LU1989771016.USD","LU0321505868.SGD","LU0096364046.USD","IE0009354923.USD","BK4007","LU0306806265.USD","LU1883839398.USD","LU0225284248.USD","LU1430594728.SGD","IE0002141913.USD","BK4585","IE00BFTCPJ56.SGD","LU0306807586.USD","LU1323610961.USD","LU0456855351.SGD","LU1983299246.USD","LU1093756168.USD","LU1261432733.SGD","LU1868837136.USD","LU1718418525.SGD","LU0321505439.SGD","BK4532","LU1571399168.USD","LU1868836757.USD","LU0237698245.USD","RNA","LU1670710588.SGD","LU1585245621.USD","LU1670710661.SGD","LU2360032135.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD","LU0868494617.USD","LU2242646821.SGD","LU0985481810.HKD","LU1868837300.USD","IE00BSNM7G36.USD","LU1670711123.USD","LU1868836591.USD","BK4139","BK4534","LU0882574055.USD","LU2133065610.SGD","BK4505","LU0061475181.USD","IE00BFXG1179.USD","LU1074936037.SGD","LU1032466523.USD","BMY","BK4588","IE00B2B36J28.USD","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123489677","title":"Atrium Therapeutics 有望获得高达13.5亿美元研发里程碑付款、8.25亿美元商业里程碑付款及分层特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1123489677","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123489677?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:02","pubTimestamp":1776945720,"startTime":"0","endTime":"0","summary":"生物技术公司Atrium Therapeutics Inc（RNA）宣布，其与制药巨头施贵宝（BMY）达成的合作协议中，包含丰厚的潜在财务回报。根据协议条款，Atrium有资格获得最高可达13.5亿美元的研发里程碑付款。\n此外，协议还涵盖了商业成功方面的激励。该公司有望进一步获得高达8.25亿美元的基于销售额的商业里程碑付款。除了这些一次性付款，合作协议还规定Atrium将获得基于产品净销售额的分层特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1323610961.USD","IE00BJT1NW94.SGD","BMY","LU0061475181.USD","IE00BFTCPJ56.SGD","LU0237698245.USD","LU1670710588.SGD","RNA","LU1983299246.USD","LU0114720955.EUR","LU1430594728.SGD","BK4505","LU0306807586.USD","LU1585245621.USD","IE00BFXG1179.USD","LU1670711040.USD","LU1868837300.USD","LU0321505439.SGD","LU0432979614.USD","BK4139","BK4007","BK4534","LU0225771236.USD","IE00B2B36J28.USD","LU0882574055.USD","LU0096364046.USD","LU1074936037.SGD","IE0002141913.USD","LU1093756325.SGD","IE0009355771.USD","BK4588","LU1868836757.USD","IE00BJJMRZ35.SGD","LU1093756168.USD","LU1868836591.USD","LU2125154935.USD","BK4559","IE0009354923.USD","LU2242652126.USD","LU2125154778.USD","IE00BSNM7G36.USD","LU0306806265.USD","LU1261432733.SGD","LU1868836914.USD","LU1670710661.SGD","LU0985481810.HKD","LU2242646821.SGD","LU2360032135.SGD","LU1291159041.SGD","LU1670711123.USD","LU0321505868.SGD","LU0267386448.USD","LU2133065610.SGD","LU0868494617.USD","BK4585","LU1868837136.USD","LU1571399168.USD","LU1718418525.SGD","LU0456855351.SGD","LU1883839398.USD","LU1989771016.USD","LU1032466523.USD","BK4581","BK4532","LU0225284248.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142269574","title":"勃林格殷格翰：BioNTech将提供Pumitamig并担任Ib/II期研究监管申办方","url":"https://stock-news.laohu8.com/highlight/detail?id=1142269574","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142269574?lang=zh_cn&edition=full","pubTime":"2026-04-09 20:14","pubTimestamp":1775736864,"startTime":"0","endTime":"0","summary":"勃林格殷格翰宣布，BioNTech公司将负责供应实验性药物Pumitamig，并作为Ib/II期临床研究的监管申办方。这项合作标志着双方在肿瘤治疗领域迈出关键一步。\n该研究将评估Pumitamig在特定患者群体中的安全性与有效性。通过整合资源与专业能力，两家企业旨在加速创新疗法的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1718418525.SGD","IE0002141913.USD","BMY","BK4532","LU1883839398.USD","LU1074936037.SGD","LU0096364046.USD","LU2133065610.SGD","IE00BFTCPJ56.SGD","LU0306807586.USD","LU1571399168.USD","LU1989771016.USD","LU0306806265.USD","IE00BJJMRZ35.SGD","LU1323610961.USD","LU1670710588.SGD","LU1670711040.USD","IE00BFXG1179.USD","LU2125154935.USD","LU1868837300.USD","IE00BSNM7G36.USD","LU0868494617.USD","LU2242646821.SGD","IE00B2B36J28.USD","LU0456855351.SGD","BK4588","BK4585","LU0985481810.HKD","LU2125154778.USD","LU0225284248.USD","LU1868836757.USD","LU1868836914.USD","LU1868836591.USD","LU0225771236.USD","BK4007","LU1868837136.USD","BK4559","LU0237698245.USD","LU1670711123.USD","LU0321505868.SGD","IE00BJT1NW94.SGD","LU1093756325.SGD","LU2242652126.USD","LU1093756168.USD","LU1585245621.USD","LU1032466523.USD","LU1983299246.USD","LU1670710661.SGD","LU1430594728.SGD","BK4534","LU0321505439.SGD","LU0061475181.USD","LU1261432733.SGD","BK4581","LU2360032135.SGD","IE0009355771.USD","LU0882574055.USD","LU0114720955.EUR","LU1291159041.SGD","LU0267386448.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188985398","title":"勃林格殷格翰将评估Dll3靶向T细胞衔接器联合PD-L1/VEGF-A双特异性抗体治疗小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1188985398","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188985398?lang=zh_cn&edition=full","pubTime":"2026-04-09 20:13","pubTimestamp":1775736791,"startTime":"0","endTime":"0","summary":"勃林格殷格翰宣布将开展临床研究，评估其Dll3靶向T细胞衔接器与PD-L1/VEGF-A双特异性抗体联合疗法在小细胞肺癌治疗中的潜力。该联合方案旨在通过不同机制协同作用，为这种侵袭性肺癌患者探索新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1261432733.SGD","BK4585","LU1074936037.SGD","LU1868836591.USD","LU2360032135.SGD","LU1323610961.USD","LU1291159041.SGD","IE00BJT1NW94.SGD","LU0306807586.USD","IE0009355771.USD","LU0306806265.USD","LU0321505868.SGD","LU0985481810.HKD","LU2133065610.SGD","LU1868837136.USD","LU1670711123.USD","LU0882574055.USD","IE00B2B36J28.USD","LU1983299246.USD","BK4588","LU1430594728.SGD","LU0225771236.USD","LU1585245621.USD","BMY","LU1989771016.USD","LU1093756168.USD","LU1883839398.USD","LU0321505439.SGD","LU1571399168.USD","BK4559","LU1670710661.SGD","LU0114720955.EUR","LU1032466523.USD","LU0267386448.USD","LU2125154935.USD","IE0002141913.USD","IE00BSNM7G36.USD","LU1868836914.USD","IE00BFXG1179.USD","BK4534","IE00BFTCPJ56.SGD","LU0456855351.SGD","LU1868837300.USD","LU2125154778.USD","LU1670711040.USD","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU2242646821.SGD","LU0096364046.USD","LU0237698245.USD","LU0061475181.USD","BK4532","LU2242652126.USD","LU0225284248.USD","LU1718418525.SGD","LU0868494617.USD","BK4581","LU1670710588.SGD","LU1868836757.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111160887","title":"勃林格殷格翰：BioNTech与合作方保留各自资产完整权利，协议为互不排他性","url":"https://stock-news.laohu8.com/highlight/detail?id=1111160887","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111160887?lang=zh_cn&edition=full","pubTime":"2026-04-09 20:07","pubTimestamp":1775736435,"startTime":"0","endTime":"0","summary":"根据最新协议条款，勃林格殷格翰宣布与BioNTech及其合作方达成的共识确认：各方将完全保留对自身资产的所有权及相关权益。\n此次签订的协议具有互不排他特性，意味着合作双方在保持各自知识产权独立性的同时，仍可与其他合作伙伴开展同类业务。该安排为各方在生物医药领域的持续创新与多元化合作预留了灵活空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1261432733.SGD","BK4585","LU1074936037.SGD","LU1868836591.USD","LU2360032135.SGD","LU1323610961.USD","LU1291159041.SGD","IE00BJT1NW94.SGD","LU0306807586.USD","IE0009355771.USD","LU0306806265.USD","LU0321505868.SGD","LU0985481810.HKD","LU2133065610.SGD","LU1868837136.USD","LU1670711123.USD","LU0882574055.USD","IE00B2B36J28.USD","LU1983299246.USD","BK4588","LU1430594728.SGD","LU0225771236.USD","LU1585245621.USD","BMY","LU1989771016.USD","LU1093756168.USD","LU1883839398.USD","LU0321505439.SGD","LU1571399168.USD","BK4559","LU1670710661.SGD","LU0114720955.EUR","LU1032466523.USD","LU0267386448.USD","LU2125154935.USD","IE0002141913.USD","IE00BSNM7G36.USD","LU1868836914.USD","IE00BFXG1179.USD","BK4534","IE00BFTCPJ56.SGD","LU0456855351.SGD","LU1868837300.USD","LU2125154778.USD","LU1670711040.USD","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU2242646821.SGD","LU0096364046.USD","LU0237698245.USD","LU0061475181.USD","BK4532","LU2242652126.USD","LU0225284248.USD","LU1718418525.SGD","LU0868494617.USD","BK4581","LU1670710588.SGD","LU1868836757.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143053047","title":"牛津生物治疗与施贵宝达成战略合作 共同研发实体瘤新一代T细胞衔接器","url":"https://stock-news.laohu8.com/highlight/detail?id=1143053047","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143053047?lang=zh_cn&edition=full","pubTime":"2026-04-09 19:03","pubTimestamp":1775732595,"startTime":"0","endTime":"0","summary":"牛津生物治疗公司宣布与全球制药巨头施贵宝建立战略合作伙伴关系，双方将聚焦于实体瘤治疗领域，共同探索和开发新一代T细胞衔接器技术。这一合作旨在通过创新免疫疗法突破现有治疗瓶颈，为实体瘤患者提供更精准、高效的治疗方案。T细胞衔接器作为肿瘤免疫治疗的前沿方向，能够特异性激活患者自身免疫系统攻击癌细胞，在临床应用中展现出巨大潜力。此次强强联合将整合牛津生物治疗公司的专有抗体平台与施贵宝的全球研发资源，加速创新疗法的转化落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505868.SGD","BK4559","IE00BSNM7G36.USD","LU1983299246.USD","LU2242652126.USD","BK4581","LU0985481810.HKD","LU1670711040.USD","LU1718418525.SGD","LU1093756168.USD","LU2125154778.USD","LU0225284248.USD","IE00BFXG1179.USD","BK4588","LU0225771236.USD","LU0114720955.EUR","IE00BJT1NW94.SGD","IE0009355771.USD","LU1989771016.USD","LU2360032135.SGD","LU2242646821.SGD","LU0061475181.USD","LU1093756325.SGD","LU1670710661.SGD","LU1670711123.USD","LU1585245621.USD","BK4532","LU0882574055.USD","LU1430594728.SGD","LU2133065610.SGD","LU1883839398.USD","LU1291159041.SGD","IE00BFTCPJ56.SGD","LU1868836591.USD","LU0237698245.USD","LU1868837136.USD","LU1571399168.USD","LU0306806265.USD","IE0002141913.USD","LU0267386448.USD","LU1868836914.USD","BMY","LU1323610961.USD","LU1032466523.USD","LU0306807586.USD","BK4585","LU1074936037.SGD","LU0868494617.USD","IE00BJJMRZ35.SGD","LU0321505439.SGD","BK4534","LU1261432733.SGD","LU1670710588.SGD","BK4007","IE00B2B36J28.USD","LU1868837300.USD","LU0096364046.USD","LU0456855351.SGD","LU1868836757.USD","LU2125154935.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626902114","title":"上海医药：公司挂牌转让上海施贵宝项目正有序推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2626902114","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626902114?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:15","pubTimestamp":1775722547,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：董秘您好，请问公司挂牌转让所持上海施贵宝股份进展如何？公司今年对创新药研发计划投入由增加吗？上海医药（601607.SH）4月9日在投资者互动平台表示，公司挂牌转让上海施贵宝项目正有序推进中，相关交易进展公司会按照监管要求及时履行信息披露义务，请您继续关注公司公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604093699584342.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093699584342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1291159041.SGD","BK4532","BK4585","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU1868837136.USD","LU1323610961.USD","LU0061475181.USD","IE00BFTCPJ56.SGD","BK4588","02607","BMY","LU1670711123.USD","LU0114720955.EUR","BK0188","IE00B2B36J28.USD","LU0096364046.USD","LU1868836914.USD","LU1032466523.USD","LU0225771236.USD","LU1883839398.USD","BK0184","BK0183","BK0012","LU1868836757.USD","LU0882574055.USD","LU0321505439.SGD","BK1197","BK0020","LU0237698245.USD","BK0028","LU0267386448.USD","LU0306807586.USD","BK4559","LU1074936037.SGD","LU1868837300.USD","LU1585245621.USD","BK4534","LU0321505868.SGD","LU2133065610.SGD","601607","LU0985481810.HKD","LU2242646821.SGD","LU2242652126.USD","BK0187","LU1670711040.USD","BK0209","LU1261432733.SGD","LU2360032135.SGD","LU2125154935.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623362213","title":"施贵宝(BMY.US)新药Camzyos三期临床告捷 有望成首款青少年罕见心脏病疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2623362213","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623362213?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:04","pubTimestamp":1774836292,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，施贵宝于周日公布了其心脏病药物Camzyos三期临床试验的积极结果，该药物有望成为首款获批用于罹患罕见重症心脏病青少年群体的治疗方案。施贵宝表示，基于该药物已在成人患者中获批应用的基础，本次数据支持Camzyos拓展至青少年适应症的开发潜力。若该适应症最终获得监管机构批准，Camzyos将为这类患病青少年提供全新治疗选择，有望改善临床症状，并降低患者接受侵入性手术治疗的需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"施贵宝(BMY.US)新药Camzyos三期临床告捷 有望成首款青少年罕见心脏病疗法","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1868836757.USD","LU1571399168.USD","LU1670711040.USD","LU0225284248.USD","LU0306806265.USD","LU1291159041.SGD","LU0225771236.USD","LU1093756325.SGD","LU1868836591.USD","LU1261432733.SGD","LU1868837136.USD","LU2125154935.USD","LU1670711123.USD","LU1032466523.USD","LU0096364046.USD","IE00BFXG1179.USD","LU0114720955.EUR","LU2125154778.USD","LU1585245621.USD","IE0009355771.USD","LU0237698245.USD","BK4532","LU1883839398.USD","BK4585","LU2360032135.SGD","LU0267386448.USD","LU0061475181.USD","LU0321505868.SGD","LU1074936037.SGD","LU2242646821.SGD","BK4007","LU0306807586.USD","BMY","BK4588","LU0321505439.SGD","LU0868494617.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU2242652126.USD","IE00BSNM7G36.USD","IE00B2B36J28.USD","LU1718418525.SGD","LU1670710661.SGD","LU1868836914.USD","LU0985481810.HKD","LU0456855351.SGD","LU0882574055.USD","LU1430594728.SGD","IE00BJJMRZ35.SGD","LU1323610961.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153187319","title":"施贵宝：Camzyos在青少年中的安全性特征与成人群体相似","url":"https://stock-news.laohu8.com/highlight/detail?id=1153187319","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153187319?lang=zh_cn&edition=full","pubTime":"2026-03-29 23:47","pubTimestamp":1774799230,"startTime":"0","endTime":"0","summary":"施贵宝公司公布的研究数据显示，其药物Camzyos在青少年患者群体中展现出的安全性特征，与已在成人患者中确立的安全性数据基本一致。\n这一发现为Camzyos在更广泛年龄层患者中的应用提供了重要的安全依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","IE00BSNM7G36.USD","LU1868836591.USD","LU1291159041.SGD","BK4532","BK4585","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU1868837136.USD","LU1323610961.USD","LU1571399168.USD","LU0061475181.USD","BK4581","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4588","BMY","LU0114720955.EUR","IE00B2B36J28.USD","LU0096364046.USD","LU1093756168.USD","LU1868836914.USD","LU1032466523.USD","LU0225771236.USD","LU1883839398.USD","LU2125154778.USD","BK4007","LU1868836757.USD","LU0882574055.USD","LU0321505439.SGD","LU0237698245.USD","LU1074936037.SGD","LU0267386448.USD","IE00BJT1NW94.SGD","BK4559","LU0306806265.USD","LU0306807586.USD","LU0456855351.SGD","LU1670710661.SGD","LU1868837300.USD","LU1585245621.USD","BK4534","LU0321505868.SGD","LU1718418525.SGD","LU2133065610.SGD","LU0225284248.USD","LU0868494617.USD","LU0985481810.HKD","LU1989771016.USD","LU2242646821.SGD","IE00BFXG1179.USD","LU2242652126.USD","LU1670710588.SGD","LU1670711040.USD","LU1670711123.USD","LU1261432733.SGD","LU2360032135.SGD","LU1430594728.SGD","LU2125154935.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142677348","title":"施贵宝SCOUT-HCM试验达到主要终点：第28周左心室流出道压差显著降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1142677348","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142677348?lang=zh_cn&edition=full","pubTime":"2026-03-29 23:46","pubTimestamp":1774799171,"startTime":"0","endTime":"0","summary":"施贵宝公司宣布，其SCOUT-HCM临床试验在第28周时成功达到主要研究终点，数据显示患者左心室流出道压差实现显著降低。\n该结果验证了实验性疗法对梗阻性肥厚型心肌病的治疗潜力，为后续研发提供了关键数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU1093756325.SGD","LU1670710588.SGD","BK4581","LU1571399168.USD","LU0096364046.USD","BK4007","LU0306807586.USD","LU1093756168.USD","LU0237698245.USD","LU2125154935.USD","BK4532","LU0267386448.USD","LU1868836757.USD","LU0985481810.HKD","IE0002141913.USD","LU1585245621.USD","LU0882574055.USD","LU1032466523.USD","LU1074936037.SGD","LU0114720955.EUR","LU2242652126.USD","BMY","LU1868836591.USD","LU1670711123.USD","BK4559","IE00B2B36J28.USD","BK4588","LU0061475181.USD","LU0225284248.USD","LU1430594728.SGD","LU1868837300.USD","LU2242646821.SGD","LU1291159041.SGD","LU0321505439.SGD","LU0868494617.USD","LU1868837136.USD","IE00BJJMRZ35.SGD","IE00BSNM7G36.USD","LU2133065610.SGD","IE0009355771.USD","LU1718418525.SGD","LU0321505868.SGD","LU0456855351.SGD","LU1989771016.USD","LU0225771236.USD","LU2125154778.USD","LU1261432733.SGD","LU0306806265.USD","LU1670710661.SGD","IE00BFTCPJ56.SGD","LU1883839398.USD","IE00BJT1NW94.SGD","LU1670711040.USD","LU2360032135.SGD","LU1868836914.USD","IE00BFXG1179.USD","BK4585","LU1323610961.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100294344","title":"施贵宝公布3期SCOUT-HCM试验积极结果：Camzyos（Mavacamten）在青少年症状性梗阻性肥厚型心肌病患者中展现显著疗效与安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=1100294344","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100294344?lang=zh_cn&edition=full","pubTime":"2026-03-29 23:45","pubTimestamp":1774799114,"startTime":"0","endTime":"0","summary":"施贵宝近日公布了其3期SCOUT-HCM临床试验的积极数据，该研究评估了Camzyos（通用名：Mavacamten）在青少年症状性梗阻性肥厚型心肌病患者中的疗效与安全性。试验结果证实，该药物在此患者群体中表现出显著的治疗效果和良好的安全特性。\n梗阻性肥厚型心肌病是一种心肌异常增厚的慢性疾病，常导致心脏血流受阻。此次针对青少年患者的临床试验达到主要终点，为这一难治性疾病提供了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1718418525.SGD","LU0306807586.USD","LU1670710661.SGD","LU0225771236.USD","LU1074936037.SGD","IE00B2B36J28.USD","BK4534","LU1868836591.USD","LU1883839398.USD","LU1670710588.SGD","LU1670711123.USD","LU2242652126.USD","LU0237698245.USD","BK4559","LU0225284248.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","BK4585","LU1868837136.USD","LU0868494617.USD","LU1093756325.SGD","LU1868836757.USD","BK4588","BMY","LU0061475181.USD","BK4532","LU1571399168.USD","LU1585245621.USD","LU2360032135.SGD","LU1291159041.SGD","LU2125154935.USD","LU0985481810.HKD","IE00BFTCPJ56.SGD","LU1670711040.USD","LU1261432733.SGD","LU1868836914.USD","IE00BJT1NW94.SGD","LU2242646821.SGD","LU0456855351.SGD","BK4007","BK4581","LU2125154778.USD","IE00BFXG1179.USD","LU1093756168.USD","LU1323610961.USD","LU1032466523.USD","LU2133065610.SGD","LU0321505439.SGD","LU1989771016.USD","LU0114720955.EUR","LU0306806265.USD","LU0096364046.USD","LU0321505868.SGD","LU1868837300.USD","LU0882574055.USD","LU1430594728.SGD","LU0267386448.USD","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128671176","title":"施贵宝：开放标签门诊转换研究显示，从口服非典型抗精神病药过渡至Cobenfy期间症状稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1128671176","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128671176?lang=zh_cn&edition=full","pubTime":"2026-03-28 19:14","pubTimestamp":1774696452,"startTime":"0","endTime":"0","summary":"一项由施贵宝开展的开放标签门诊转换研究证实，患者在从口服非典型抗精神病药物转换至Cobenfy的治疗过程中，其精神症状能够保持稳定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670711040.USD","LU1032466523.USD","LU0985481810.HKD","LU1868836591.USD","LU1670710661.SGD","LU1989771016.USD","LU1868836914.USD","BK4581","IE0002141913.USD","LU1323610961.USD","LU0306806265.USD","LU0321505868.SGD","LU0456855351.SGD","LU1261432733.SGD","LU2125154935.USD","LU2242646821.SGD","BK4585","IE0009355771.USD","BK4559","LU0237698245.USD","LU0061475181.USD","LU0868494617.USD","IE00BSNM7G36.USD","BMY","LU1868836757.USD","LU1670711123.USD","LU0225771236.USD","LU0321505439.SGD","LU1571399168.USD","LU1718418525.SGD","LU0306807586.USD","LU1093756168.USD","LU2360032135.SGD","BK4007","LU1868837300.USD","IE00BJT1NW94.SGD","LU2133065610.SGD","LU1883839398.USD","BK4588","LU1093756325.SGD","BK4532","LU0267386448.USD","LU2125154778.USD","IE00BFXG1179.USD","LU1585245621.USD","LU1670710588.SGD","IE00BFTCPJ56.SGD","LU0882574055.USD","IE00BJJMRZ35.SGD","LU1291159041.SGD","BK4534","LU2242652126.USD","LU1868837136.USD","IE00B2B36J28.USD","LU0225284248.USD","LU0114720955.EUR","LU1430594728.SGD","LU1074936037.SGD","LU0096364046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148811954","title":"施贵宝公布Camzyos新数据，巩固其在梗阻性肥厚型心肌病领域领导地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1148811954","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148811954?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:01","pubTimestamp":1774263670,"startTime":"0","endTime":"0","summary":"在2026年美国心脏病学会年度科学会议暨博览会（ACC.26）上，施贵宝公布了其药物Camzyos（Mavacamten）的最新数据。这些新数据进一步强化了该公司在梗阻性肥厚型心肌病治疗领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670711123.USD","LU1323610961.USD","LU1585245621.USD","BK4534","IE00BJT1NW94.SGD","LU1670711040.USD","LU1670710588.SGD","LU0321505439.SGD","LU2360032135.SGD","LU1989771016.USD","IE00B2B36J28.USD","LU0267386448.USD","LU1670710661.SGD","LU1571399168.USD","LU0114720955.EUR","LU1868837300.USD","LU0306806265.USD","LU0225771236.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0882574055.USD","BK4585","LU1093756325.SGD","LU2242646821.SGD","LU1074936037.SGD","LU0225284248.USD","LU1868836757.USD","LU1093756168.USD","LU0061475181.USD","BK4588","IE00BFXG1179.USD","LU0321505868.SGD","LU0985481810.HKD","IE0002141913.USD","LU0868494617.USD","LU0096364046.USD","LU0237698245.USD","LU1718418525.SGD","LU1868836914.USD","BK4559","LU0456855351.SGD","BK4007","IE0009355771.USD","LU2242652126.USD","LU1883839398.USD","LU2133065610.SGD","LU2125154778.USD","LU1291159041.SGD","LU2125154935.USD","LU1261432733.SGD","LU1430594728.SGD","BK4532","LU1032466523.USD","IE00BSNM7G36.USD","LU1868837136.USD","LU1868836591.USD","LU0306807586.USD","BK4581","BMY"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bms.com","stockEarnings":[{"period":"1week","weight":-0.0225},{"period":"1month","weight":-0.0445},{"period":"3month","weight":-0.0116},{"period":"6month","weight":0.2213},{"period":"1year","weight":0.1376},{"period":"ytd","weight":0.0558}],"compareEarnings":[{"period":"1week","weight":0.017},{"period":"1month","weight":0.1036},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.0798},{"period":"1year","weight":0.2844},{"period":"ytd","weight":0.0614}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"百时美施贵宝公司于1933年8月在美国德拉瓦州注册成立，源自于1887年在纽约创办的企业，并在1989年因合并而重命名。作为一家生物制药公司，百时美施贵宝专注于创新药物的发现、开发、许可、生产、营销和销售，以对抗严重疾病。公司的战略方法结合了大型制药公司的资源和规模，以及生物技术行业特有的灵活性和创新重点。百时美施贵宝优先关注肿瘤学、血液学、免疫学、心血管和神经科学等领域的变革性药物，旨在提供长期价值和竞争优势。作为全球研究型制药公司，百时美施贵宝的产品在全球范围内销售，服务于包括批发商、分销商和特药药房在内的多种实体，并在多个国家保持着重要的生产运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.478261,"avgChangeRate":-0.011323},{"month":2,"riseRate":0.565217,"avgChangeRate":0.011855},{"month":3,"riseRate":0.630435,"avgChangeRate":0.007963},{"month":4,"riseRate":0.468085,"avgChangeRate":-0.005808},{"month":5,"riseRate":0.553191,"avgChangeRate":0.001312},{"month":6,"riseRate":0.608696,"avgChangeRate":0.009417},{"month":7,"riseRate":0.413043,"avgChangeRate":-0.001733},{"month":8,"riseRate":0.521739,"avgChangeRate":-0.001022},{"month":9,"riseRate":0.521739,"avgChangeRate":0.00993},{"month":10,"riseRate":0.586957,"avgChangeRate":0.025121},{"month":11,"riseRate":0.630435,"avgChangeRate":0.022318},{"month":12,"riseRate":0.630435,"avgChangeRate":0.022265}],"exchange":"NYSE","name":"施贵宝","nameEN":"Bristol-Myers Squibb"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"施贵宝,BMY,施贵宝股票,施贵宝股票老虎,施贵宝股票老虎国际,施贵宝行情,施贵宝股票行情,施贵宝股价,施贵宝股市,施贵宝股票价格,施贵宝股票交易,施贵宝股票购买,施贵宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}